Overview of ICH E2F – Development …
Overview of ICH E2F – Development SafetyDevelopment Safety Update Report (DSUR) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
Download Overview of ICH E2F – Development …
Information
Domain:
Source:
Link to this page:
Documents from same domain
ICH HARMONISED TRIPARTITE GUIDELINE
www.ich.orgGOOD MANUFACTURING PRACTICE GUIDE FOR ACTIVE PHARMACEUTICAL INGREDIENTS ICH Harmonised Tripartite Guideline Having reached Step 4 of the ICH Process at the ICH Steering Committee meeting
Final Concept Paper Q12: Technical and Regulatory ...
www.ich.orgFINAL Q12 Concept Paper Endorsed: 9 September 2014 -3- product lifecycle management. To date, the main emphasis has been on the implementation of
Q7 Implementation Working Group ICH Q7 …
www.ich.orgInternational Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Secretariat, Chemin des Mines 9, P.O. Box 195, 1211 Geneva 20, Switzerland
GUIDELINE FOR GOOD CLINICAL PRACTICE
www.ich.orgGUIDELINE FOR GOOD CLINICAL PRACTICE INTRODUCTION Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the
ICH HARMONISED GUIDELINE
www.ich.orgE6(R1) Document History First Codification History Date New Codification November 2005 E6 Approval by the Steering Committee under Step 2 and release for public consultation.
ICH HARMONISED GUIDELINE - ICH Official web …
www.ich.orginternational conference on harmonisation of technical requirements for registration of pharmaceuticals for human use ich harmonised guideline guideline for elemental impurities
![[ICH E2F] [EXAMPLE DSUR – PHASE III …](/cache/preview/1/3/5/f/e/1/c/f/thumb-135fe1cf2cdb82799c462ad0ea089c48.jpg)
[ICH E2F] [EXAMPLE DSUR – PHASE III …
www.ich.orgfictional document for illustrative purposes only document date: 5 october 2010 [ich e2f] [example dsur – phase iii investigational drug] zb3579
ADDENDUM TO ICH E11: CLINICAL INVESTIGATION …
www.ich.org3 ICH HARMONISED GUIDELINE ADDENDUM TO ICH E11: CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS IN THE PEDIATRIC POPULATION E11 (R1) ICH Consensus Guideline Released for Adoption on 18 August 2017, at Step 4 of the ICH
M4Q Implementation Working Group Questions & …
www.ich.org1. Introduction This document is intended to provide additional guidance for the preparation of an application file in the CTD-Q format (see section 2: General Issues).
I ADDENDUM TO ICH E6(R1 ... - ICH Official web site
www.ich.orgi ICH HARMONISED GUIDELINE INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE ICH E6(R2) Draft ICH Consensus Guideline Released for Consultation on 11 June 2015, at Step 2 of the ICH Process
Related documents
ICH guideline E2F on development safety update …
www.ema.europa.euThe Development Safety Update Report (DSUR) proposed in this guideline is intended to be a common standard for periodic reporting on drugs under development (including marketed drugs that are under
DEVELOPMENT SAFETY UPDATE REPORT - ICH
www.ich.orgThe Development Safety Update Report (DSUR) proposed in this guideline is intended to be a common standard for periodic reporting on drugs under development (including
Drug Development 1.2 Procedures for Clinical Trials
www.jpma.or.jp37 Basic standards for periodically reporting safety information during the development phase, common to all drugs, etc., are available in “Development Safety Update
Post-marketing Surveillance of Drugs - JPMA
www.jpma.or.jp73 CHAPTER 4 Post-marketing Surveillance of Drugs . Post-marketing surveillance (PMS) to assure the quality, efficacy and safety of drugs after they go on the market and
Medicines Control Council
www.mccza.comRegistration of Medicines Reporting of Adverse Drug Reactions 2.11_ADR_reporting_May03_v1_2.doc December 2012 Page 1 of 18 MEDICINES CONTROL COUNCIL REPORTING ADVERSE DRUG REACTIONS
DEVELOPMENT OF PAEDIATRIC MEDICINES: …
www.who.intworking document qas/08.257/rev.3 august 2011 restricted development of paediatric medicines: points to consider in pharmaceutical development
STABILITY TESTING OF ACTIVE PHARMACEUTICAL …
www.who.intWorking document QAS/17.694 page 2 30 SCHEDULE FOR THE PROPOSED ADOPTION PROCESS OF DOCUMENT 31 QAS/17.694: 32 STABILITY TESTING OF ACTIVE PHARMACEUTICAL INGREDIENTS 33 AND FINISHED PHARMACEUTICAL PRODUCTS 34 Development of the proposal to update the guideline for stability testing of active pharmaceutical ingredients and
Related search queries
ICH guideline E2F on development safety update, Development Safety Update Report, Development, DEVELOPMENT SAFETY UPDATE REPORT - ICH, Procedures for Clinical Trials, Safety, Development Safety Update, Post-marketing Surveillance of Drugs, MEDICINES CONTROL COUNCIL, DEVELOPMENT OF PAEDIATRIC MEDICINES:, Development of paediatric medicines: points to consider in pharmaceutical development, PHARMACEUTICAL, FINISHED PHARMACEUTICAL PRODUCTS, Update, Pharmaceutical ingredients and